Using Ranibizumab for Eye Problems from VKH Syndrome
Author Information
Author(s): Kolomeyer A. M., Roy M. S., Chu D. S.
Primary Institution: The Institute of Ophthalmology and Visual Science, University of Medicine and Dentistry of New Jersey
Hypothesis
The study aims to describe the effectiveness of intravitreal ranibizumab for treating choroidal neovascularization associated with Vogt-Koyanagi-Harada syndrome.
Conclusion
Despite initial improvement in vision with ranibizumab, the choroidal neovascularization recurred and led to permanent vision loss.
Supporting Evidence
- The patient initially improved after treatment with ranibizumab.
- Vision decreased again due to recurrent choroidal neovascularization.
- Chronicity of VKH may lead to permanent vision loss.
Takeaway
A woman with eye problems got better after treatment, but her vision got worse again because the problem came back.
Methodology
Interventional case report.
Limitations
The study is based on a single case, limiting generalizability.
Participant Demographics
50-year-old Hispanic woman.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website